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Dermal Fibroblasts, Interleukin 15 and Chronic In¯ammation
In this issue, the ®ndings reported by Rappl et al (p. 102) add
to the growing evidence that dermal ®broblasts play a
signi®cant role in chronic in¯ammation. The authors' work
suggests that activated (but not resting) T lymphocytes in the
dermis, are further stimulated by direct contact with activated
®broblasts expressing membrane-bound IL-15. This results in
maintenance of the state of activation of T cells and promotion
of chronic in¯ammation. The data indicate that cultured dermal
®broblasts constitutively produce IL-15, but that this remains
con®ned to the ®broblast cytoplasm and is only translocated to
the plasma membrane, where it is expressed as a functional
membrane-bound protein, under the prolonged in¯uence of
TNFa. Therefore, this mechanism requires pre-existing in¯am-
mation with local TNFa production, and the availability of
preactivated T lymphocytes, and appears to be relevant to the
maintenance or ampli®cation rather than initiation of chronic
in¯ammation. The potential importance of this process is
highlighted by the authors' ®nding that membrane-bound IL-
15 is expressed in vivo on dermal ®broblasts in chronically
in¯amed skin, as shown by immunohistochemistry. Monocytes
are a rich source of IL-15, however, and constitutively express
this cytokine on the cell surface, even when unstimulated.
Therefore, the question remains as to the relative importance of
dermal ®broblasts versus monocytes as a source of biologically
active IL-15 in chronic skin in¯ammation. The cytokine
nevertheless appears to be an attractive therapeutic target in
chronic in¯ammatory skin disease.
Hyaluronic Acid, CD44, and Melanoma
The extracellular matrix is not only important in cell adhesion but
generates a diversity of functional signals in adhering cells via
speci®c cellular receptors. Hyaluronic acid (HA) is a ubiquitous
component of the extracellular matrix, and appears to interact with
cells via at least two receptors, CD44 and so-called Receptor for
HA-Mediated Motility/Intracellular HA-Binding Protein
(RHAMM/IHABP). Ahrens et al (p. 93) report their studies on
the functional importance of these two receptors in melanoma cells.
Previous work has shown that highly metastatic melanoma cell lines
synthesize increased amounts of HA. HA has also been found to
enhance proliferation of other cells, but its role in melanoma cell
proliferation and the receptor(s) involved have been unclear.
Ahrens et al now show that highly tumorigenic melanoma cell lines
express enhanced levels of both CD44 and RHAMM/IHABP
mRNA and protein, but that only the CD44 protein is expressed
on the cell surface, the RHAMM/IHABP protein remaining
con®ned to the cell cytoplasm. In line with this, adherence of
melanoma cells to HA was mediated mainly by CD44, as anti-
CD44 but not RHAMM/IHABP antibody inhibited this process.
The authors also show that HA causes concentration-dependent
increases of melanoma cell proliferation, that this is also selectively
inhibited by the CD44 but not RHAMM/IHABP antibody, and
that HA-induced proliferation may be mediated in part by CD44-
dependent production of TGFb1 and bFGF. This writer therefore
thinks it reasonable to consider HA itself as an autocrine growth
factor for melanoma cells, as suggested by the enhanced synthesis of
HA by melanoma cells of high metastatic potential, and the
increased, CD44-dependent melanoma cell growth in the presence
of HA (whether a direct effect or in part dependent on production
of other growth factors). Will blockade of CD44±HA interactions
be of any value in the therapy of proliferative disorders including
malignant melanoma?
Dermatologist, Test Your Son's Hair
Anyone who is familiar with the state of this writer's scalp will
understand his particular interest in the intriguing work reported by
Choi et al from Korea (p. 57). Although the precise etiology of
male pattern baldness is unclear and there appears to be no
consistent mode of inheritance, it is thought to be associated with
the enhanced androgen activity generated through conversion of
testosterone to dihydrotestosterone (DHT) by 5a-reductase in the
follicular environment. In support of this is the evidence that
®nasteride, a 5a-reductase inhibitor, promotes hair growth in
balding men. Because the correlation between plasma androgen
levels and baldness appears to be controversial, further work is
needed to clarify the pathogenesis of male pattern baldness by
measurement of actual steroid hormones in the microenvironment
of the hair follicle. Choi et al now report an interesting study of
androgen-related steroid levels in extracts of hair clippings from
balding men, their sons (aged 8±16 y), and nonbalding controls.
Hair clippings from all parts of the scalp were thoroughly washed to
remove potentially contaminating steroids in sebum, sweat and
from other nonfollicular sources. Following an established extrac-
tion procedure incorporating stable isotope internal standards,
residues were derivatized and subjected to quantitative gas
chromatography-mass spectrometry. This is generally accepted as
one of the most quantitative and speci®c analytical methods
available and is used, for example, in doping control laboratories.
By using these methods, the authors have demonstrated the
presence of testosterone, DHT, and epitestosterone in hair extracts.
The latter is of interest as it is reported to have antiandrogenic
properties by virtue of its ability to inhibit the action of 5a-
reductase on testosterone. The authors' major ®ndings include
signi®cantly higher levels of DHT and especially testosterone in the
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hair of the balding men than in aged-matched, nonbalding controls.
Of particular interest was the marked increase in testosterone/
epitestosterone (T/E) ratios in the balding men and all their sons,
compared with the control groups. The sons of balding fathers had
a mean T/E ratio about three times greater than that of the control
sons, without exception, and the difference between the fathers'
ratios was even greater. The authors conclude, provocatively, that
male pattern baldness may be predicted by measurement of the
three steroids in hair, and that this may allow early therapeutic
intervention in predisposed young men. This writer notes that the
hormonal changes were seen in all sons of balding men, however,
and suggests that more work is needed to determine whether the
biochemical analysis is a more reliable predictor than the simple
presence of a balding father. Furthermore, the mode of inheritance
of male pattern baldness is the subject of some controversy,
particularly in Caucasian races in which it is very common, and it
appears to depend on whether baldness is of early or late onset.
Therefore, if genetic studies show that consistent vertical transmis-
sion from father to son is not the rule, the demonstration of similar
biochemical changes in the hair of balding fathers and their sons
may not be a reliable indicator of the sons' predisposition to
baldness. Perhaps the described hormonal changes are necessary but
not suf®cient for baldness to occur. Other genetic in¯uence may be
critical, and consistent with the views of some, that male pattern
baldness is multifactorial. The authors also rightly point out that this
work needs to be extended to other racial groups and that work on
genes relating to production and activity of epitestosterone may be
of interest in determining the genetic basis of this condition.
Finally, and on a completely different note, will we now see the
emergence of athletes with trendy, close-shaven hairstyles which
will prevent the sampling of hair for analysis of steroid hormones
consumed over the preceding months?
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